(Reuters) - U.S. regulators on Thursday approved BioMarin Pharmaceutical Inc's Palynziq for adults with phenylketonuria, a rare metabolic disorder, sending shares of the biotechnology company up 3 percent after hours. The drug, an injected …
SAN RAFAEL, Calif., June 7, 2018 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the Company received $20 million in milestone payments from Pfizer Inc. These milestone payments were triggered by …
BioMarin Pharmaceutical Inc. (BMRN) said that it received standard approval from the U.S. Food and Drug Administration for Palynziq (pegvaliase-pqpz) Injection to reduce blood phenylalanine or Phe concentrations in adult patients with …
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on BMRN at https://www.zacks.com/ap/BMRN
Yahoo!1mon
Mr. Jean-Jacques Bienaime serves as Chairman of the Board, Chief Executive Officer of Biomarin Pharmaceutical Inc., He joined our Board in May 2005, the same time that he became our Chief Executive Officer, and was named Chair of the …
The risk-reward has certainly improved, yet I am not pulling the trigger yet. BioMarin (BMRN) is a much debated stock even as its stock has been trading in a relative narrow $80-100 trading range so far this year, actually trading towards the …
BioMarin Pharmaceutical Inc. announced its most recent results for valoctocogene roxaparvovec at the 2017 American Society of Hemophilia event over the weekend. Valoctocogene roxaparvovec is a treatment for severe hemophilia. “We …
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on BMRN at https://www.zacks.com/ap/BMRN
BioMarin Pharmaceutical Inc. announced its most recent results for valoctocogene roxaparvovec at the 2017 American Society of Hemophilia event over the weekend. Valoctocogene roxaparvovec is a treatment for severe hemophilia. “We …